JBIO.US Jade Biosciences, Inc.
- Market cap
- USD 1.03B
- P/E
- -
- P/B
- 2.33x
- ROE
- -43.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is JBIO.US undervalued?
Graham numberThe Graham number of Jade Biosciences, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jade Biosciences, Inc. fundamental analysis
No fundamental analysis for Jade Biosciences, Inc. yet.
Jade Biosciences, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, In…
Full company profileJade Biosciences, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jade Biosciences, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | - | - | - | - | 0.00 | 0.00 |
| Gross Profit | -1.00K | -15.0K | -68.0K | -96.0K | -282K | -26.0K | -36.0K |
| Operating Income | -8.89M | -23.0M | -53.2M | -81.4M | -74.6M | -114M | -205M |
| EBITDA | -9.54M | -22.9M | -51.4M | -75.4M | -69.3M | -127M | -199M |
| Net Income | -9.61M | -23.0M | -51.5M | -75.5M | -69.6M | -127M | -192M |
| EPS | -14 | -33 | -74 | -100 | -85 | -4.06 | -3.15 |
| Balance Sheet | |||||||
| Total Assets | 4.72M | 175M | 135M | 127M | 80.3M | 350M | 472M |
| Total Liabilities | 1.77M | 2.95M | 8.56M | 18.0M | 3.90M | 17.3M | 32.2M |
| Shareholders' Equity | 2.94M | 172M | 127M | 109M | 76.4M | 333M | 440M |
| Cash & Short-term Investments | 4.57M | 167M | 129M | 122M | 78.6M | 336M | 461M |
| Total Debt | - | 574K | 1.09M | 675K | 417K | 724K | 628K |
| Cash Flow | |||||||
| Operating Cash Flow | -7.86M | -27.4M | -39.1M | -56.8M | -71.2M | -94.7M | -129M |
| Capital Expenditure | 0.00 | 181K | 195K | 142K | 0.00 | 196K | 0.00 |
| Free Cash Flow | -7.86M | -27.6M | -39.3M | -56.9M | -71.2M | -94.9M | -129M |
| Ratios | |||||||
| ROE | -326.8% | -13.3% | -40.6% | -69.0% | -91.1% | -38.3% | -43.7% |
| ROA | -203.8% | -13.1% | -38.1% | -59.3% | -86.7% | -36.4% | -40.7% |
| Debt to Equity | - | 0.00x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jade Biosciences, Inc. dividends
Jade Biosciences, Inc. has not paid dividends in the last 6 fiscal years.
Last stock split: 1:35 on Apr 29, 2025.
Who owns Jade Biosciences, Inc.
- Insiders 1.10%
- Institutions 98.90%
- Public & others 0.00%
- Shares outstanding 63.6M
- Free float 56.5M
Top funds holding JBIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 1.84M | 2.89% | +2.69% | Oct 2026 |
| Polar Capital Biotech S Inc | 1.75M | 2.75% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.70M | 2.67% | 0.00% | Sep 2026 |
| Fidelity Growth Company Fund | 1.19M | 1.87% | 0.00% | Aug 2026 |
| Franklin Small Cap Value A | 1.06M | 1.67% | -34.80% | Sep 2026 |
| iShares Russell 2000 ETF | 1.00M | 1.58% | 0.00% | Oct 2026 |
| Fidelity Select Health Care | 1.00M | 1.57% | +22.01% | Aug 2026 |
| Janus Henderson Global Life Sciences D | 988K | 1.55% | 0.00% | Sep 2026 |
| Janus Global Life Science AUSD | 964K | 1.52% | +38.07% | Sep 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 963K | 1.51% | +28.88% | Jun 2026 |
| Fidelity Advisor Biotechnology I | 961K | 1.51% | +29.57% | Sep 2026 |
| Janus Henderson Glb Life Scn I2 USD | 946K | 1.49% | +3.12% | Aug 2026 |
| Franklin Biotechnology Discv A(acc)USD | 936K | 1.47% | +5.44% | Sep 2026 |
| Fidelity Stock Selector Small Cap | 908K | 1.43% | 0.00% | Aug 2026 |
| Pictet-Biotech P USD | 819K | 1.29% | +69.53% | Jul 2026 |
| Fidelity Small Cap Growth | 780K | 1.23% | 0.00% | Aug 2026 |
| JPMorgan Small Cap Growth A | 645K | 1.01% | -0.61% | Sep 2026 |
| Fidelity Series Small Cap Opps | 589K | 0.93% | 0.00% | Aug 2026 |
| Franklin Biotechnology Discovery A | 509K | 0.80% | +6.01% | Sep 2026 |
| Fidelity Advisor Health Care I | 500K | 0.79% | 0.00% | Sep 2026 |
Top institutions holding JBIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 9.13M | 13.61% | +28.81% | Jun 2026 |
| Jupiter Topco LLC | 6.27M | 9.35% | 0.00% | Jun 2026 |
| Fairmount Funds Management LLC | 4.55M | 6.79% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 3.67M | 5.47% | 0.00% | Jun 2026 |
| VR Adviser, LLC | 3.22M | 4.80% | 0.00% | Jun 2026 |
| Bellevue Group AG | 3.06M | 4.56% | -12.67% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 2.86M | 4.26% | 0.00% | Jun 2026 |
| BlackRock Inc | 2.80M | 4.18% | +21.07% | Jun 2026 |
| Franklin Templeton Inc | 2.79M | 4.16% | 0.00% | Jun 2026 |
| State Street Corp | 2.34M | 3.48% | +256.16% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.24M | 3.35% | +24.94% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.91M | 2.85% | 0.00% | Jun 2026 |
| Polar Capital Holdings PLC | 1.85M | 2.75% | 0.00% | Jun 2026 |
| Avidity Partners Management LP | 1.70M | 2.54% | -39.29% | Jun 2026 |
| Remedium Capital Partners, LLC | 1.58M | 2.35% | 0.00% | Jun 2026 |
| Soleus Capital Management, L.P. | 1.55M | 2.31% | +94.63% | Jun 2026 |
| JPMorgan Chase & Co | 1.48M | 2.20% | +9,198.87% | Jun 2026 |
| Baker Bros Advisors LP | 1.23M | 1.83% | -25.03% | Jun 2026 |
| Logos Global Management LP | 1.13M | 1.68% | +181.25% | Jun 2026 |
| Versant Venture Management LLC | 992K | 1.48% | -35.00% | Jun 2026 |
Jade Biosciences, Inc. company profile
- Company name
- Jade Biosciences, Inc.
- Ticker
- JBIO.US
- Exchange
- USA Stocks
- Listed since
- Jun 30, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 55
- Fiscal year end
- December
- Address
- Building 23, Waltham, MA, United States, 02453
- Phone
- 781 312 3013
- Website
- jadebiosciences.com
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Jade Biosciences, Inc. management
10- Mr. Tom FrohlichPresident, CEO & Director · born 1976
- Mr. Bradford D. Dahms Ph.D.CFO & Treasurer · born 1989
- Dr. Andrew James King BVMS, D.V.M., Ph.D.President of Research & Development · born 1980
- Ms. Elizabeth Balta J.D.Chief Legal Officer & Corporate Secretary · born 1971
- Ms. Lori StewartSenior Vice President of People
- Mr. Jonathan QuickSenior Vice President of Finance
- Ms. Valerie FauvelleSenior Vice President of Regulatory & Quality
- Ms. Amy SullivanSenior Vice President of Development Operations
- Ms. Sandy LewisSenior Vice President, Biometrics & Clinical Strategy
- Dr. Edward R. Conner M.D.Chief Medical Officer · born 1973